Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Virology

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    72 result(s) found for: Virology. Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2011-005700-15 Sponsor Protocol Number: marha1983 Start Date*: 2013-01-07
    Sponsor Name:Lennart Svensson Linköping University Medical Faculty
    Full Title: Can 5-HT3 receptor antagonists be used to limit vomiting in rota- and norovirus infections?
    Medical condition: Virus caused vomiting and effect of the antiemetic drug Ondansetron
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-001107-20 Sponsor Protocol Number: MDT-637-CP-201 Start Date*: 2013-08-02
    Sponsor Name:MicroDose Therapeutx, Inc., a wholly owned subsidiary of Teva Pharmaceuticals Industries, Ltd.
    Full Title: A Phase 2a Randomised, Double-Blind, Placebo-Controlled Repeat Dose Trial of the Activity of MDT-637 in Healthy Subjects Challenged with RSV-A (Memphis 37b)
    Medical condition: RSV Infection
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10038717 Respiratory syncytial viral infections HLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-001735-39 Sponsor Protocol Number: CMX001-999 Start Date*: Information not available in EudraCT
    Sponsor Name:Chimerix, Inc
    Full Title: An Open-label, Randomized, Multi-center, Parallel Group, Two-arm Study to Assess the Safety, Overall Tolerability, and Antiviral Activity of Brincidofovir versus Standard of Care for Treatment of A...
    Medical condition: Treatment of adenovirus infections in high-risk pediatric allogeneic hematopoietic cell transplant recipients
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10060931 Adenovirus infection PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IE (Completed) DE (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended) FR (Completed) NL (Prematurely Ended) GB (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2016-001950-16 Sponsor Protocol Number: ISI-2015-1 Start Date*: 2017-03-03
    Sponsor Name:Isifer AB
    Full Title: A randomized, double blind, controlled, parallel group, multi-centre phase II clinical study of lidocaine pertubation as a treatment for couples with unexplained infertility
    Medical condition: Unexplained infertility
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: PL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-000149-53 Sponsor Protocol Number: D-STAPH Start Date*: 2014-05-06
    Sponsor Name:Karolinska University Hospital, Huddinge
    Full Title: ’D-STAPH’ Vitamin D supplementation to persistent carriers of MRSA – A double blind, randomised controlled trial
    Medical condition: Persistent MRSA carriers
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-000623-16 Sponsor Protocol Number: 1100.1454 Start Date*: 2004-12-13
    Sponsor Name:Boehringer Ingelheim Ltd
    Full Title: A retrospective study to compare the 3-year antiviral efficacy of nevirapine and efavirenz in combination with D4T and 3TC in 2NN patients
    Medical condition: Treatment of HIV-1 infection
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2009-011464-11 Sponsor Protocol Number: VX08-950-112 Start Date*: 2009-10-20
    Sponsor Name:Vertex Pharamceuticals, Inc.
    Full Title: EXTEND: A 3-Year, Virology, Follow-up Study in Subjects Previously Treated With Telaprevir in Select Clinical Studies
    Medical condition: Hepatitis C virus infection
    Disease: Version SOC Term Classification Code Term Level
    12.0 10019752 Hepatitis C virus (HCV) LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2021-000724-35 Sponsor Protocol Number: 216912 Start Date*: 2021-05-11
    Sponsor Name:Vir Biotechnology, Inc.
    Full Title: A Multicenter, Randomized, Double-Blind, Parallel Group Phase II Study to Evaluate the Safety, Tolerability and Pharmacokinetics of a Second Generation VIR-7831 Material in Non-Hospitalized Partici...
    Medical condition: Non-Hospitalized Participants with Mild to Moderate Coronavirus Disease 2019 (COVID-19)
    Disease: Version SOC Term Classification Code Term Level
    23.1 10021881 - Infections and infestations 10084401 COVID-19 respiratory infection LLT
    23.0 10021881 - Infections and infestations 10084268 COVID-19 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2019-001588-63 Sponsor Protocol Number: 200925 Start Date*: 2020-10-23
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: An open label, single arm study to evaluate single and multiple dose pharmacokinetics, safety and tolerability, and to explore clinical outcomes of treatment with intravenous (IV) zanamivir in neon...
    Medical condition: Influenza
    Disease:
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: PL (Prematurely Ended) GB (GB - no longer in EU/EEA) NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-005645-38 Sponsor Protocol Number: TBEB08 Start Date*: 2008-01-17
    Sponsor Name:Clinical Institute of Virology, Medical University of Vienna
    Full Title: B-cell memory and humoral immune response after primary immunization against tick borne encephalitis (TBE) in the elderly
    Medical condition: This study will investigate immunity against tick-borne encephalitis (TBE) following primary TBE vaccination in healthy volunteers 18-30 years or > 60 years who fulfill the local criteria for TBE v...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10036897 Prophylactic vaccination LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2012-004231-24 Sponsor Protocol Number: TBEB13 Start Date*: 2013-03-05
    Sponsor Name:Department für Virologie, Medizinische Universität Wien
    Full Title: Long-term immunity after primary vaccination against tick-borne encephalitis in the elderly
    Medical condition: long-term B-cell immunity against tick-borne encephalitis (TBE) in healthy volunteers who have received 3-dose primary vaccination at an age between 18 and 31 years or older than 60 years.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2006-007100-42 Sponsor Protocol Number: 15581 Start Date*: 2007-01-29
    Sponsor Name:Turku University Hospital
    Full Title: Viral Inception of Asthma: Prospective study from infancy to early school-age.
    Medical condition: First wheezing episode (=acute expiratory breathing difficulty) associated with rhinovirus infection in 3 to 23 -month-old children.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10047925 Wheezing expiratory LLT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: FI (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-002928-41 Sponsor Protocol Number: Immunity_TBE Start Date*: 2013-01-14
    Sponsor Name:Med. Uni. Wien, Klinik für Innere I
    Full Title: Characterization of humoral and cellular immunity for tick-borne encephalitis (TBE) vaccination in allogeneic blood and marrow graft recipients: a pilot study
    Medical condition: Characterization of humoral and cellular immunity for tick-borne encephalitis (TBE) vaccination in allogeneic blood and marrow graft recipients: a pilot study Study group consists of patients 11...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2018-000034-36 Sponsor Protocol Number: CHDR1734_CLS003-CO-PR-004 Start Date*: 2018-08-10
    Sponsor Name:Cutanea Life Sciences
    Full Title: A phase 2, randomized, double blind, vehicle controlled, parallel group study to explore the efficacy, pharmacodynamics and safety of topical ionic contra-viral therapy (ICVT), comprised of digoxin...
    Medical condition: Actinic keratosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10000614 Actinic keratosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2012-002408-42 Sponsor Protocol Number: RB-UK-12-0004 Start Date*: 2012-11-29
    Sponsor Name:Reckitt Benckiser Pharmaceuticals Inc.
    Full Title: An Open-label, Randomised, Three -Way, Cross-Over Study to Assess the Pharmacokinetics, Safety and Tolerability of Two Formulations of RBP-6300 10mg in Healthy Volunteers under a Naltrexone Block i...
    Medical condition: Maintenance/substitution agent for the treatment of opioid dependence.
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004873 10012346 Dependence on opiates LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-003984-37 Sponsor Protocol Number: CMX001-211 Start Date*: 2018-07-30
    Sponsor Name:Chimerix, Inc
    Full Title: A Randomized, Controlled, Open-Label, Multiple Ascending Dose Study of Intravenous Brincidofovir in Adult Allogeneic Hematopoietic Cell Transplant Recipients with Adenovirus Viremia
    Medical condition: Treatment of adenovirus infections in adult allogeneic hematopoietic cell transplant recipients
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10060931 Adenovirus infection PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-005366-34 Sponsor Protocol Number: WV43042 Start Date*: 2021-02-12
    Sponsor Name:F. Hoffmann La Roche Ltd.
    Full Title: A PHASE II RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE ANTIVIRAL ACTIVITY, SAFETY, PHARMACOKINETICS, AND EFFICACY OF RO7496998 (AT-527) IN NON-HOSPITALIZED ADULT PATIENTS WI...
    Medical condition: Coronavirus disease 2019 (COVID-19)
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004862 10084401 COVID-19 respiratory infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) BG (Completed) ES (Completed) LV (Completed) GR (Completed) LT (Completed)
    Trial results: View results
    EudraCT Number: 2010-020083-38 Sponsor Protocol Number: NV25118 Start Date*: 2010-10-12
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A Multicenter, Study of the Safety of Oseltamivir Administered Intravenously for the Treatment of Influenza in Patients Aged ≥13 Years
    Medical condition: Treatment of Influenza [seasonal or pandemic (H1N1) 2009]
    Disease: Version SOC Term Classification Code Term Level
    14.0 10021881 - Infections and infestations 10022001 Influenza (epidemic) LLT
    14.0 10021881 - Infections and infestations 10022003 Influenza B virus infection LLT
    14.0 10021881 - Infections and infestations 10022000 Influenza PT
    14.0 10021881 - Infections and infestations 10022002 Influenza A virus infection LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed) LT (Prematurely Ended) DK (Prematurely Ended) FR (Ongoing) IT (Prematurely Ended) ES (Prematurely Ended) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-002169-21 Sponsor Protocol Number: CP40563 Start Date*: 2018-11-19
    Sponsor Name:Roche Farma SA que realiza un el ensayo en España y que actúa como representante de F. Hoffmann-La Roche Ltd
    Full Title: A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, ACTIVE (OSELTAMIVIR)-CONTROLLED STUDY TO ASSESS THE SAFETY, PHARMACOKINETICS, AND EFFICACY OF BALOXAVIR MARBOXIL IN OTHERWISE HEALTHY PEDIATRIC PATIENTS 1 T...
    Medical condition: Influenza
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10022001 Influenza (epidemic) LLT
    20.1 100000004862 10022003 Influenza B virus infection LLT
    20.1 100000004862 10022002 Influenza A virus infection LLT
    20.0 100000004862 10016790 Flu LLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: ES (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2018-001416-30 Sponsor Protocol Number: CP40617 Start Date*: 2018-12-12
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE III, RANDOMIZED, DOUBLE-BLIND PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BALOXAVIR MARBOXIL IN COMBINATION WITH STANDARD-OF-CARE NEURAMINIDASE INHIBITOR IN...
    Medical condition: INFLUENZA
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10016790 Flu LLT
    20.0 100000004862 10022001 Influenza (epidemic) LLT
    20.1 100000004862 10022003 Influenza B virus infection LLT
    20.1 100000004862 10022002 Influenza A virus infection LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed) EE (Completed) CZ (Completed) SE (Completed) BE (Completed) DE (Completed) FR (Completed) FI (Completed) HU (Completed) ES (Completed) RO (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 21:44:57 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA